PDF herunterladen
Horm Metab Res 2019; 51(09): 602-607
DOI: 10.1055/a-0897-8565
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Association Between Visfatin and Hepatic Steatosis in the General Population During Long-Term Follow-Up

Katharina Johannsen
1   Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany
,
Marion Flechtner-Mors
7   Division of Sports- and Rehabilitation Medicine, Ulm University Hospital, Ulm, Germany
,
Wolfgang Kratzer
1   Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany
,
Wolfgang Koenig
2   Department of Internal Medicine II, Ulm University Hospital, Ulm, Germany
3   German Heart Centre Munich, Technical University of Munich, Munich, Germany
4   DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
,
Bernhard Otto Boehm
1   Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany
5   Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
6   Imperial College London, London, UK
,
Julian Schmidberger
1   Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany
,
for the EMIL-Study group › Institutsangaben
Weitere Informationen

Publikationsverlauf

received 21. Januar 2019

accepted 17. April 2019

Publikationsdatum:
27. Mai 2019 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

The aim of this study was to investigate any association between the adipose tissue-derived protein, visfatin, and non-alcoholic fatty liver disease (NAFLD) and its potential long-term impact on hepatic steatosis. A cross-sectional study including 2429 randomly selected subjects was performed in 2002. Later, 403 subjects were re-evaluated in 2013. Serum visfatin concentrations were determined by sandwich enzyme-linked immunosorbent assay. Phenotyping included abdominal ultrasonography, anthropometric data, and laboratory investigations. No association was found between circulating visfatin levels and the presence of NAFLD at baseline (2002: p=0.0967) or during follow-up (2013: p=0.1312). However, a significant increase in visfatin levels in relation to the level of steatosis was seen during follow-up (p<0.0001). During the more than 10-year follow-up, the metabolic status of the study subjects worsened, with a significant increase in body mass index (BMI) (p<0.0001), waist-to-hip ratio (p<0.0001), triglycerides (TG) (p<0.0001), low-density lipoprotein (p=0.0305), homeostasis model assessment (p<0.0001), and presence of diabetes (p<0.0001). This change was accompanied by an increase in serum visfatin levels, which showed a weak correlation with BMI (p<0.0001, r=0.27586) and presence of diabetes (p<0.0043, r=0.14188). A statistically significant correlation between leucocyte numbers and serum visfatin concentration (p<0.0001, r=0.25615) was found. We found no association between visfatin levels and the presence or absence of NAFLD or the degree of hepatic fatty infiltration at baseline. There was a strong correlation between serum visfatin concentrations and the number of leucocytes, which may suggest a proinflammatory role for visfatin.

Key words

NAFLD - Nampt - PBEF - obesity
 

  • References

  • 1 Younossi ZM, Koenig AB, Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
    CrossrefPubMedGoogle Scholar
  • 2 Al-Dayyat HM, Rayyan YM, Tayyem RF. Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors. Diabetes Metab Syndr 2018; 12: 569-575
    CrossrefPubMedGoogle Scholar
  • 3 Hardy T, Oakley F, Anstee QM. et al. Nonalcoholic fatty liver disease: Pathogenesis and disease spectrum. Annu Rev Pathol 2016; 11: 451-496
    CrossrefPubMedGoogle Scholar
  • 4 Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016; 65: 1062-1079
    CrossrefPubMedGoogle Scholar
  • 5 Curat CA, Wegner V, Sengenès C. et al. Macrophages in human visceral adipose tissue: Increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-747
    CrossrefPubMedGoogle Scholar
  • 6 Gómez R, Conde J, Scotece M. et al. What’s new in our understanding of the role of adipokines in rheumatic diseases?. Nat Rev Rheumatol 2011; 7: 528-635
    CrossrefPubMedGoogle Scholar
  • 7 Ouchi N, Parker JL, Lugus JJ. et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97
    CrossrefPubMedGoogle Scholar
  • 8 Auguet T, Terra X, Porras JA. et al. Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. Clin Biochem 2013; 46: 202-208
    CrossrefPubMedGoogle Scholar
  • 9 Berndt J, Klöting N, Kralisch S. et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916
    CrossrefPubMedGoogle Scholar
  • 10 Haider DG, Holzer G, Schaller G. et al. The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr 2006; 43: 548-549
    CrossrefPubMedGoogle Scholar
  • 11 Chen M-P, Chung F-M, Chang D-M. et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299
    CrossrefPubMedGoogle Scholar
  • 12 Filippatos TD, Derdemezis CS, Gazi IF. et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008; 38: 71-72
    PubMedGoogle Scholar
  • 13 Sandeep S, Velmurugan K, Deepa R. et al. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007; 56: 565-570
    CrossrefPubMedGoogle Scholar
  • 14 Akbal E, Koçak E, Taş A. et al. Visfatin levels in nonalcoholic fatty liver disease. J Clin Lab Anal 2012; 26: 115-119
    CrossrefPubMedGoogle Scholar
  • 15 Jarrar MH, Baranova A, Collantes R. et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412-421
    PubMedGoogle Scholar
  • 16 Genc H, Dogru T, Kara M. et al. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann Hepatol 2013; 12: 548-555
    PubMedGoogle Scholar
  • 17 Dahl TB, Holm S, Aukrust P. et al. Visfatin/NAMPT: A multifaceted molecule with diverse roles in physiology and pathophysiology. Annu Rev Nutr 2012; 32: 229-243
    CrossrefPubMedGoogle Scholar
  • 18 Gaddipati R, Mitnala S, Padaki N. et al. Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. Ann Hepatol 2010; 9: 266-270
    CrossrefPubMedGoogle Scholar
  • 19 WHO. Obesity: Preventing and managing the global epidemic. Report of a WHO Consultation (TRS 894). Geneva, World Health Organization (WHO) 2000
    PubMed
  • 20 Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis 2007; 11: 37-54
    CrossrefPubMedGoogle Scholar
  • 21 Qayyum A, Chen DM, Breiman RS. et al. Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: Which modality is best?. Clin Imaging 2009; 33: 110-115
    CrossrefPubMedGoogle Scholar
  • 22 Aller R, De Luis DA, Izaola O. et al. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci 2009; 54: 1772-1777
    CrossrefPubMedGoogle Scholar
  • 23 Kukla M, Ciupinska-Kajor M, Kajor M. et al. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. Pol J Pathol 2010; 61: 147-153
    PubMedGoogle Scholar
  • 24 Hassan AB, Khni AN. Assessment of visfatin and risk factors in relation with diabetic mellitus Type II. Life Sci J 2014; 11: 608-615
    PubMedGoogle Scholar
  • 25 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017; 14: 32-42
    CrossrefPubMedGoogle Scholar
  • 26 Enroth S, Hallmans G, Grankvist K. et al. Effects of long.term storage time and original sampling month on biobank plasma protein concentrations. E Bio Med 2016; 12: 309-314
    PubMedGoogle Scholar
  • 27 Graham C, Chooniedass R, Stefura WP. et al. Stability of pro- and anti-inflammatory immune biomarkers for human cohort studies. J Transl Med 2017; 15: 53
    CrossrefPubMedGoogle Scholar
  • 28 Mohamadkhani A, Poustchi H. Repository of human blood derivative biospecimens in biobank: Technical implications. Middle East J Digest. Diseases 2015; 7: 61-68
    PubMedGoogle Scholar